Followers | 4 |
Posts | 204 |
Boards Moderated | 0 |
Alias Born | 01/09/2017 |
Sunday, April 09, 2017 4:54:48 PM
this is from the PR
The market for male sexual dysfunction is dominated by Viagra and Cialis both are taken orally for Erectile Dysfunction (ED). The Company's alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.
It would seem promescent finished clinical trials of their (ED) in 2014.https://clinicaltrials.gov/ct2/show/NCT02241460 .
2nd) Given the amount of time the product has been available, it is clear that Promescent is not a leader but a new kid on the block. I Think Viagra and Cialis are the still the dominate leader's in (ED), that is why Viaderma is competing against them(the idea is to be the best). Given the good doctors Transdermal tech, I think it is a high probability that the poduct Viaderma produces will be significantly more effective in treating (ED) than the other competitors(IMO). I do not have % numbers to give but that's my two cents.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM